Intuitive Surgical Inc (ISRG)

Shares of Intuitive Surgical (ISRG) dropped by 2.39% from $273.45 to $266.91 in the trading on Friday, October 20, 2023. The reason why ISRG stock down is due to its Q3 FY2023 earnings.

• Earnings Beat: ISRG reported earnings of $1.46 per share, beating the analyst consensus estimate of $1.41 per share.
• Missed Sales Estimate: However, the company's sales of $1.74 billion fell short of the expected $1.77 billion.
• Outlook Adjustments: ISRG revised its FY23 procedure volume outlook to 21%-22% and cut its gross margin outlook to 68.0%-68.5%, reflecting uncertainty in healthcare, slowing bariatric growth, and manufacturing challenges.

Intuitive Surgical Stock (ISRG) dropped by 5.56% from $281.79 to $266.12 in the trading on Thursday October 12, 2023. The reasons why ISRG stock down today include

• Decreased Stock Position: Baillie Gifford & Co. decreased its holdings in shares of Intuitive Surgical, Inc. by 1.4% during the 2nd quarter.
• Quarterly Earnings Schedule: ISRG is scheduled to announce its earnings results after the market closes on Thursday, October 19th. Analysts expect the company to announce earnings of $1.41 per share for the quarter.

Shares of Intuitive Surgical (ISRG) dropped by 5.39% from $297.83 to $281.79 in the trading on Wednesday, October 11, 2023. The reason why ISRG stock down is due to a competitor's successful kidney disease prevention drug. However, the stock drop was not exclusive to Intuitive, as some other dialysis companies like DaVita and Baxter International also suffered losses. This market turbulence was triggered by Novo Nordisk's early termination of a phase 3 trial for Ozempic (semaglutide), which showed remarkable effectiveness in slowing kidney disease progression in type 2 diabetes and chronic kidney disease patients, potentially disrupting the need for dialysis. This setback compounded Inituitive's existing struggles, now that the announcement by Novo Nordisk hurts kidney dialysis provider.